Gravity Analytica

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KALV 11.12.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-19

Name of Upcoming Event:Stifel 2024 Healthcare Conference

Date of Upcoming Event:2024-11-21

Name of Upcoming Event:Jefferies London Healthcare Conference

Full Press Release SEC Filings Our KALV Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.&SALISBURY, England--(BUSINESS WIRE)--Nov. 12, 2024--KalVista Pharmaceuticals, Inc.(NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences:

Stifel 2024 Healthcare Conference onTuesday, November 19, 2024, at9:10 a.m. EST
Jefferies London Healthcare ConferenceonThursday, November 21, 2024, at11:00 a.m. GMT

Each presentation will be live webcast on the Company’s website atwww.kalvista.com. After the presentations, an audio archive will be available on KalVista’s website for 30 days.

AboutKalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet need. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by theU.S.FDA with a PDUFA goal date ofJune 17, 2025. In addition, we have completed marketing authorization application (MAA) submissions for sebetralstat to theEuropean Medicines Agencyas well as theUnited Kingdom,Switzerland,Australia, andSingapore, and we anticipate filing a MAA inJapanin late 2024.

For more information aboutKalVista, please visitwww.kalvista.comor follow on social media at@KalVistaandLinkedIn.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of theU.S.Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with theSecurities and Exchange Commission, including in our annual report on Form 10-K for the year endedApril 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with theSecurities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241112749536/en/

Jenn SnyderVice President, Corporate Affairs(617) 448-0281jsnyder@kalvista.comRyan BakerHead, Investor Relations(617) 771-5001ryan.baker@kalvista.com

Source:KalVista Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com